Prospects for the treatment of phenylketonuria by gene therapy

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 5, Issue 2, 1999, Pages 136-143

  Eisensmith, Randy C ^a   Kuzmin, Alexei I ^a   Krougliak, Valeri A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Immunomodulation; Non viral vectors; Phenylketonuria (PKU); Recombinant adeno associated virus; Recombinant adenovirus; Recombinant lentivirus; Recombinant retrovirus; Viral vectors

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 6; MESSENGER RNA; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; AMINO ACID METABOLISM; ARTICLE; DIET THERAPY; ENZYME DEFICIENCY; GENE MUTATION; GENE SILENCING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; INBORN ERROR OF METABOLISM; MOLECULAR CLONING; NONHUMAN; PHENYLKETONURIA; PRIORITY JOURNAL; RETROVIRUS; VIRUS RECOMBINANT;

EID: 0032969653     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1999)5:2<136::AID-MRDD8>3.0.CO;2-F     Document Type: Article

References (103)

1. Alemany R, Dai Y, Lou YC, et al. 1997. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods 68:147-159.
2. Armentano D, ZabnerJ, Sacks C, et al. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 71:2408-2416.
3. Bajocchi G, Feldman SH, Crystal RG, et al. 1993. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors Nat Genet 3:229-234.
4. Barr D, Tubb T, Ferguson D, et al. 1995. Strain-related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 2:151-155.
5. Bick U, Fahrendorf G, Ludolph AC, et al. 1991. Disturbed myelination in patients with treated hyperphenylalaninemia: evaluation with magnetic resonance imaging. Eur J Pediatr 150: 185-189.
6. Bickel H, Gerrard J, Hickmans EM. 1954. The influence of phenylalanine intake on the chemistry and behavior of a phenylketonuria child. Acta Paediatr Scand 43:64-77.
7. Bridge E, Pettersson U. 1995. Nuclear organization of replication and gene expression in adenovirus-infected cells. Curr. Top. Microbiol. Immunol. 199:99-117.
8. Brough DE, Hsu C, Kulesa VA, et al. 1997. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 71:9206-9213.
9. Chen HH, Mack LM, Kelly R, et al. 1997. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 94:1645-1650.
10. Chirmule N, Hughes JV, Gao GP, et al. 1998. Role of E4 in eliciting T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998;72: 6138-6145.
11. Corbeau P, Kraus G, Wong-Staal F. 1996. Efficient gene transfer by a human immunodeficiency virus 1 [HIV-2]-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 93:14070-14075.
12. Crawfurd MD, Gibbs DA, Sheppard DM. 1981. Studies on human phenylalanine monooxygenase. I. restricted expression. J Inherited Metab Dis 4:191-195.
13. Cress WD, Nevins JR. 1996. Use of the E2F transcription factor by DNA tumor virus regulatory proteins. Curr. Top. Microbiol. Immunol. 208:63-78.
14. Dedieu JF, Vigne E, Torrent C, et al. 1997. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 71:4626-4637.
15. Duan D, Sharma P, Yang J, et al. 1998. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72:8568-8577.
16. Eisensmith RC, Woo SLC. 1995. Molecular genetics of phenylketonuria: From molecular anthropology to gene therapy. In: Hall JC, Dunlap JC, Friedmann T, Gianelli F, editors. Advances in genetics, Volume 32. San Diego: Academic Press. p 199-272.
17. Elkon KB, Liu CC, Gall JG, et al. 1997. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 94:9814-9819.
18. Engelhardt JF, Ye X, Doranz B, et al. 1994a. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91:6196-6200.
19. Engelhardt JF, Ye X, Doranz B, et al. 1994b. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91:6196-6200.
20. Fang B, Eisensmith RC, Li XHC, et al. 1994. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1:247-254.
21. Fang B, Eisensmith RC, Wang H, et al. 1995. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6:1039-1044.
22. Fang B, Wang H, Gordon G, et al. 1996. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and dogs. Gene Ther 3:217-222.
23. Feng M, Jackson WH Jr, Goldman CK, et al. 1997. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 15:866-870.
24. Ferrari FK, Samulski T, Shenk T, et al. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70: 3227-3234.
25. Ferry N, Duplessis O, Houssin D, et al. 1991. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci USA 88:8377-8381.
26. Fisher KJ, Choi H, Burda J, et al. 1996a. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22.
27. Fisher KJ, Gao GP, Weitzman MD, et al. 1996b. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 70:520-532.
28. Fisher KJ, Jooss K, Alston J, et al. 1997. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3:306-312.
29. Fisher KJ, Kelley WM, Burda JF, et al. 1996. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 7:2079-2087.
30. Floyd SS Jr, Clemens PK, Ontell MR, et al. 1998. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 5:19-30.
31. Galli C, Agostini C, Mosconi C, et al. 1991. Reduced plasma C-20 and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. J Pediatr 119:562-567.
32. Gao GP, Yang Y, Wilson JM. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70:8934-8943.
33. Goldman MJ, Litzky LA, Engelhardt JF, et al. 1995. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study. Hum Gene Ther 6:839-851.
34. Gorziglia MI, Kadan MJ, Yei S, et al. 1996. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 70:4173-4178.
35. Gropper SS, Acosta PB, Clarke-Sheehan N, et al. 1988. Trace element status of children with PKU and normal children. J Am Diet Assoc 88:459-465.
36. Gupta S, Aragona E, Vemuru RP, et al. 1991. Permanent engraftment and function of hepatocytes delivered to the liver: Implications for gene therapy and liver repopulation. Hepatology 14:144-149.
37. Haecker SE, Stedman HH, Bailee-Gordon RJ, et al. 1996. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 7:1907-1914.
38. Hauser MA, Amalfitano A, Kumar-Singh R, et al. 1997. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscul Disord 7:277-283.
39. Herz J, Gerard RD. 1993. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 90:2812-2816.
40. Herzog RW, Hagstrom JN, Kung SH, et al. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94:5804-5809.
41. Hohmann HP, Remy R, Poschl B, et al. 1990. Tumor necrosis factors-alpha and -beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NK-kappa B at low receptor occupancy and within minutes after receptor binding. J Biol Chem 265:15183-15188.
42. Imperiale MJ, Akusjnarvi G, Leppard KN. 1995. Post-transcriptional control of adenovirus gene expression. Curr. Top. Microbiol. Immunol. 199:139-171.
43. Jaffe HA, Danel C, Longenecker G, et al. 1992. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1:372-378.
44. Kaleko M, Garcia JV, Miller AD. 1991. Persistent gene expression after retroviral gene transfer into liver cells in vivo. Hum Gene Ther 2:27-32.
45. Kaplitt MG, Leone P, Samulski RJ, et al. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8:148-154.
46. Kaufman S. 1989. An evaluation of the possible neurotoxicity of metabolites of phenylalanine. J Pediatr 114:895-900.
47. Kay MA, Holterman AX, Meuse L. 1995. Selective immune inhibition of recombinant adenovirus vectors using soluble CTLA4Ig results in persistent gene expression from hepatocytes in vivo. Nat Genet 11:191-197.
48. Kay MA, Landen CN, Rothenberg SR, et al. 1994. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 91:2353-2357.
49. 1-antitrypsin in mice after direct gene delivery in vivo. Hum Gene Ther 3:641-647.
50. Kay MA, Meuse L, Gown AM, et al. 1997. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 94:4686-4691.
51. Kay MA, Rothenberg S, Landen C, et al. 1993. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX deficient dogs. Science 262:117-119.
52. Koeberl DD, Alexander IE, Halbert CL, et al. 1997. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 94:1426-1431.
53. Kolls JK, Lei D, Odom G, et al. 1996. Use of CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Human Gene Ther 7:489-497.
54. Kosai KI, Finegold MJ, Thi Huynh BT, et al. 1998. Retrovirus-mediated in vivo gene transfer in replicating liver using recombinant hepatocyte growth factor without liver injury or partial hepatectomy. Hum Gene Ther 9:1293-1301.
55. Kuzmin AI, Finegold MJ, Eisensmith RC. 1997. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 4:309-316.
56. Kwok SCM, Ledley FD, DiLella AG, et al. 1985. Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. Biochemistry 24:556-561.
57. Ledley FD, Grenett HE, DiLella AG, et al. 1985. Gene transfer and expression of human phenylalanine hydroxylase. Science 228:77-79.
58. Ledley FD, Grenett H, McGinnis-Shelnutt M, et al. 1986. Retroviral-mediated gene transfer of human phenylalanine hydroxylase into NIH 3T3 and hepatoma cells. Proc Natl Acad Sci USA 83:409-413.
59. Lenke RR, Levy HL. 1980. Maternal phenylketonuria and hyperphenylalaninemia: An international survey of the outcome of untreated and treated pregnancies. N Engl J Med 303:1202-1208.
60. Leppard KN. 1997. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. J Gen Virol 78:2131-2138.
61. Li J, Fang B, Eisensmith RC, et al. 1995. In vivo gene therapy for hyperlipidemia: Phenotypic correction in Watanabe rabbits by hepatic delivery of the LDL receptor gene. J Clin Invest 95:768-773.
62. Li QT, Kay M, Finegold M, et al. 1993. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 4:403-409.
63. Lieber A, He CY, Kay MA. 1997. Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotechnol 15:1383-1387.
64. Lieber A, He CY, Kirillova I. 1996. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 70:8944-8960.
65. Lieber A, He CY, Meuse L, et al. 1997. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
66. Lieber A, He CY, Meuse L, et al. 1998. Inhibition ot NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J Virol 72:9267-9277.
67. Liu TJ, Kay MA, Darlington GJ, et al. 1992. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. Som Cell and Molec Genet 18:89-96.
68. Miao CH, Snyder RO, Schowalter DB. 1998. The kinetics of rAAV integration in the liver [letter]. Nat Genet 19:13-15.
69. hph-5: a mouse mutant deficient in phenylalanine hydroxylase. Proc Natl Acad Sci USA 87:1965-1967.
70. Mitani K, Graham FL, Caskey CT, et al. 1995. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 92:3854-3858.
71. Monahan PE, Samulski RJ, Tazelaar J, et al. 1998. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 5:40-49.
72. Morral N, O'Neal W, Zhou H, et al. 1997. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 8:1275-1286.
73. Morsy MA, Gu M, Motzel S, et al. 1998. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95:7866-7871.
74. Nakai H, Herzog RW, Hagstrom JN, et al. 1998. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91:4600-4607.
75. Naldini L, Blomer U, Gallay P, et al. 1996. In vivo gene delivery and stable transduction of nondividing fells by a lentiviral vector. Science 272:263-267.
76. Parks RJ, Chen L, Anton M, et al. 1996. A helper-dependent adenovirus vector system: Removal of helper virus by Crc-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93:13565-13570.
77. Patijn GA, Lieber A, Meuse L, et al. 1998. High-efficiency retrovirus-mediated gene transfer into the livers of mice. Hum Gene Ther 9:1449-1456.
78. Patijn GA, Lieber A, Schowalter DB, et al. 1998. Hepatocyte growth factor induces hepatocyte proliferation in vivo and allows for efficient retroviral-mediated gene transfer in mice. Hepatology 28:707-716.
79. Peng H, Armentano D, MacKenzie-Graham L, et al. 1988. Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes. Proc Natl Acad Sci USA 85:8146-8150.
80. Poeschla EM, Wong-Staal F, Looney DJ. 1998. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4:354-357.
81. Ponder K, Gupta S, Leland F, et al. 1991. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci USA 88:1217-1221.
82. Rosenfeld MA, Siegfried W, Yoshimura K, et al. 1991. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252:431-434.
83. Schiedner G, Morral N, Parks RJ, et al. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nat Genet 18:180-183.
84. Scriver CR, Kaufman S, Eisensmith RC, et al. 1995. The hyperphenylalaninemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, Volume 1, 7th ed. New York: McGraw-Hill. p 1015-1075.
85. Seljelid R, Eskeland T. 1993. The biology of macrophages: I. general principles and properties. Eur J Haematol 51:267-275.
86. Shedlovsky A, McDonald JD, Symula D, et al. 1993. Mouse models of human phenylketonuria. Genetics 134;1205-1210.
87. Shenk T. 1996. Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Virology. Philadelphia: Lippencott-Raven. p 2111-2148.
88. Smith I, Lobascher ME, Stevenson JE, et al. 1978. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. Br Med J 2:723-726.
89. Snyder RO, Miao CH, Patijn GA, et al. 1997. Persistent and therapeutic concentrations or human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 16:270-276.
90. Stein CS, Pemberton JL, van Rooijen N, et al. 1998. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. Gene Ther 5:431-439.
91. Stratford-Perricaudet LD, Levrero M, Chasse JF, et al. 1990. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1:241-256.
92. Thompson AJ, Smith I, Kendall BE, et al. 1991. Magnetic resonance imaging changes in early treated patients with phenylketonuria. Lancet 337:1224.
93. Wilson C, Kay MA. 1995. Immunomodulation to enhance gene therapy [comment]. Nat Med 1:887-889.
94. Wolff G, Worgall S, van Rooijen N, et al. 1997. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 71:624-629.
95. Xiao X, Li J, Samulski RJ. 1996. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70:8098-8108.
96. Yang Y, Ertl HCJ, Wilson JM. 1994a. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433-142.
97. Yang Y, Greenough K, Wilson JM. 1996. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 3:412-420.
98. Yang Y, Nunes FA, Berencsi K, et al. 1994b. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407-4411.
99. Yang Y, Nunes FA, Berencsi K, et al. 1994c. Inactivation of E2a in reeombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 7:362-369.
100. Yang Y, Trinchieri G, Wilson JM. 1995. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1:890-893.
101. Zhang HG, Zhou T, Yang P, et al. 1998. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 9:1875-1884.
102. Zhou H, O'Neal W, Morral N, et al. 1996. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 70:7030-7038.
103. Zufferey R, Nagy D, Mandel RJ, et al. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871-875.